Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Gains from Sales and Divestitures (2024)

Stoke Therapeutics (STOK) has 1 years of Gains from Sales and Divestitures data on record, last reported at $748238.0 in Q4 2024.

  • For Q4 2024, Gains from Sales and Divestitures changed N/A year-over-year to $748238.0; the TTM value through Dec 2024 reached $748238.0, changed N/A, while the annual FY2024 figure was $748238.0, N/A changed from the prior year.
  • Gains from Sales and Divestitures reached $748238.0 in Q4 2024 per STOK's latest filing.
  • Across five years, Gains from Sales and Divestitures topped out at $748238.0 in Q4 2024 and bottomed at $748238.0 in Q4 2024.